Last reviewed · How we verify
IV Furosemide and PO Metolazone
IV Furosemide and PO Metolazone is a Loop diuretic and thiazide-like diuretic combination Small molecule drug developed by Rambam Health Care Campus. It is currently FDA-approved for Edema and fluid overload in heart failure, Diuretic-resistant edema in renal or hepatic disease.
IV furosemide and PO metolazone work synergistically as loop and thiazide-like diuretics to increase sodium and water excretion, reducing fluid overload.
IV furosemide and PO metolazone work synergistically as loop and thiazide-like diuretics to increase sodium and water excretion, reducing fluid overload. Used for Edema and fluid overload in heart failure, Diuretic-resistant edema in renal or hepatic disease.
At a glance
| Generic name | IV Furosemide and PO Metolazone |
|---|---|
| Sponsor | Rambam Health Care Campus |
| Drug class | Loop diuretic and thiazide-like diuretic combination |
| Target | Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, while metolazone is a thiazide-like diuretic that blocks the Na-Cl cotransporter in the distal convoluted tubule. Combined use produces a sequential nephron blockade effect, enhancing diuresis in patients with severe fluid retention or diuretic resistance.
Approved indications
- Edema and fluid overload in heart failure
- Diuretic-resistant edema in renal or hepatic disease
Common side effects
- Hypokalemia
- Hyponatremia
- Hyperuricemia
- Ototoxicity (with high-dose IV furosemide)
- Dehydration
- Hypotension
Key clinical trials
- Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload (PHASE4)
- The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study (PHASE4)
- Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure (NA)
- Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure (PHASE4)
- Protocolized Diuretic Strategy in Cardiorenal Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Furosemide and PO Metolazone CI brief — competitive landscape report
- IV Furosemide and PO Metolazone updates RSS · CI watch RSS
- Rambam Health Care Campus portfolio CI
Frequently asked questions about IV Furosemide and PO Metolazone
What is IV Furosemide and PO Metolazone?
How does IV Furosemide and PO Metolazone work?
What is IV Furosemide and PO Metolazone used for?
Who makes IV Furosemide and PO Metolazone?
What drug class is IV Furosemide and PO Metolazone in?
What development phase is IV Furosemide and PO Metolazone in?
What are the side effects of IV Furosemide and PO Metolazone?
What does IV Furosemide and PO Metolazone target?
Related
- Drug class: All Loop diuretic and thiazide-like diuretic combination drugs
- Target: All drugs targeting Na-K-2Cl cotransporter (NKCC2) and Na-Cl cotransporter (NCC)
- Manufacturer: Rambam Health Care Campus — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Edema and fluid overload in heart failure
- Indication: Drugs for Diuretic-resistant edema in renal or hepatic disease
- Compare: IV Furosemide and PO Metolazone vs similar drugs
- Pricing: IV Furosemide and PO Metolazone cost, discount & access